Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 17, 2016
Reporting Period: Fourth Quarter and Full Year ended December 31, 2015
This filing serves as a notification that the Company issued a press release and investor presentation regarding its financial results and business update for the period ended December 31, 2015.
Key Financial Metrics
The provided text is a cover document (Form 8-K) referencing a press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2). The text of the 8-K itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced exhibits which are not included in the input text.
Material Changes
The filing text does not detail specific material changes in financial performance or operations compared to prior periods. It only confirms the announcement of results for the quarter and fiscal year ended December 31, 2015.
Guidance, Outlook, and Risks
- Business Update: The filing references a "Business Update" and an "Exosomes Program Update Presentation" (Exhibit 99.2), indicating a focus on the Company's exosome technology program.
- Regulatory Disclosure: The information is furnished under Item 7.01 (Regulation FD) and Item 2.02. The Company explicitly states that this information is not deemed filed for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section unless expressly incorporated by reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and Full Year 2015.
- Examine Exhibit 99.2 (Investor Presentation) for details on the Exosomes Program progress and future milestones.
- Verify the Company's cash runway and burn rate, as these are critical for a biotechnology firm in development stages.
- Confirm if the "Business Update" includes any changes to clinical trial timelines or regulatory strategies.